The nifty pharma index is trading at 22,015.30, down 165.40 points or 0.75 per cent from the previous close of 22,180.70 close to the end of trading day. The Index Opened Higher at 22,219.65 But Witnessed Selling Pressure Through the Trading Session, with an intraday low of 21,983.20.

Market Breadth Remained Weak With 15 Stocks Declining Against only 5 advancing. Major Laggards Included Ajanta Pharma Down 2.04 per cent, Torrent Pharma Falling 1.86 per cent, and dr reddy’s declining 1.66 per cent. Cipla Led the losers with a 1.64 per cent drop to ₹ 1,512.70, while being the most active by value with trades Worth ₹ 336.07 Crres.

On the positive side, glenmark pharma emerged as the top Gainer, Rising 1.03 per cent to ₹ 2,039.40 Following Its Licensing Agreement with Hengrui Pharma for Oncology Drugy Drugy Drugy DruGy. Aurobindo Pharma and Mankind Pharma also posted modest gains.

Analyst Sentiment Remained Mixed Across the Sector. Motilal oswal maintained a boy rating on gland pharma with a target of ₹ 2,340, citing performance revival through niche us approvals. Morgan Stanley assigned an overweight rating to sun pharma with a ₹ 1,948 target, highlighting the company’s GLP-1 Market Preparations. However, nomura remained neutral on glenmark despite the licensing deal, setting a ₹ 1,500 target.

The pharma index has shown resilience over longer periods, Posting 74.58 per cent returns over three years despite recent weakness.

Published on September 25, 2025